Clinical trials: Viral Respiratory Tract Infection
SARS-CoV-2
Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran
The main objective of the study is to evaluate the safety of the elasomeran/davesomeran and andusomeran vaccines as used in routine clinical practice.
- Trial name
- NCT06130345
- Testing
- SPIKEVAX
- Where
- United States
- Volunteers
- 15,196,685 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2 Infection
Burn Injuries During COVID-19 Pandemic and Its Influence on Length of Stay
Burn injuries were thought to be difficult to treat during the new corona virus epidemic. Our goal is to determine the risk factors that influence length of hospital stay (LOS) of burn injured patients during COVID -19 pandemic.
- Trial name
- NCT06330389
- Testing
- Burn Injuries Graft Surgery
- Where
- Qatar
- Volunteers
- 70 people
- Sponsor
- Hamad Medical Corporation
COVID-19
Evaluating Auscul-X, a Touch Free Digital Stethoscope
Auscul-X a touch free digital stethoscope will permit physical distancing of healthcare providers while maintaining the ability to auscultate patients from a safe distance (over 10 feet away)
- Trial name
- NCT04570189
- Testing
- Auscul-X
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- AusculSciences Canada Inc.
COVID-19
A Study of QLS1128 and in Combination With Ritonavir in Healthy Participants
A study to evaluate safety, tolerability and pharmacokinetics of QLS1128 sustained-release tablets and in combination with ritonavir tablets in healthy participants
- Trial name
- NCT05458076
- Testing
- QLS1128 A-Dose 1~5 and Ritonavir, QLS1128 C-Dose 1~3 and Ritonavir, QLS1128 D-Dose 1 and Ritonavir
- Where
- China
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Papillomavirus Infections, Coronavirus Disease (COVID-19)
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
The purpose of this study to evaluate the safety and immunogenicity of a 2-dose regimen of 9vHPV vaccine, where the first dose is administered concomitantly with a first dose of a 2-dose regimen of mRNA-1273 vaccine versus…
- Trial name
- NCT05119855
- Testing
- 9vHPV Vaccine, mRNA-1273 Vaccine
- Where
- 38 sites in United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Covid19
Study Investigating the Effects of UVC Beam and Laser Beam Therapy According to Standard Therapy in Patients With Covid-19 Diagnosis
Clinical research study that evaluates the effect of Turkish Beam-Selective UV developed by RD GLOBAL ARAŞTIRMA GELİŞTİRME SAĞLIK İLAÇ İNŞAAT YATIRIMLARI A.Ş.
- Trial name
- NCT04642326
- Testing
- Test Group: experimental - UVC Therapy applied
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- RD Global Araştirma Geliştirme Sağlik Ilaç Inşaat Yatirimlari A.Ş.
COVID-19
A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care
In December 2019, a novel pneumonia caused by a previously unknown pathogen emerged in Wuhan, China. The pathogen was soon identified as a novel coronavirus (SARS-CoV-2), which is closely related to severe acute respiratory…
- Trial name
- NCT05195749
- Testing
- 101-PGC-005 ('005) + SOC
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- 101 Therapeutics
Suspected or Confirmed COVID-19
NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients
This open-label, randomized, and controlled clinical trial aims to determine the feasibility and effectiveness of using NBT-NM108, a novel botanical-based fixed-combination drug, to modulate the gut microbiota and treat…
- Trial name
- COVGUT20 (NCT04540406)
- Testing
- NBT-NM108, Usual Care Only
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Notitia Biotechnologies Company
Covid19
Novaferon for COVID-19 Treatment Trial (NCTT-005)
A multicenter, randomized, double-blind, placebo-controlled trial for hospitalized moderate COVID-19 patients
- Trial name
- NCT04708158
- Testing
- Novaferon
- Where
- 22 sites in Japan
- Volunteers
- 385 people
- Sponsor
- Genova Inc.
COVID-19 (Healthy Volunteers)
Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older
The primary objectives of the study were: To describe the neutralizing antibody profile at Day 1, Day 22, and Day 36 of each study intervention group.
- Trial name
- NCT04537208
- Testing
- CoV2 preS dTM-AF03 (low-dose), CoV2 preS dTM-AF03 (high-dose), CoV2 preS dTM-AS03 (low-dose)
- Where
- 11 sites in United States
- Volunteers
- 441 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19, Asymptomatic COVID-19
A Clinical Evaluation of Proof Diagnostics Test System Including the Proof Diagnostics Reader and COVID-19 Test
To determine the accuracy of Proof Diagnostics COVID-19 Test in the intended, symptomatic and suspected/at-risk asymptomatic population and point-of-care use as compared to a standard molecular comparator, Quidel Lyra SARS-CoV-2…
- Trial name
- NCT05331976
- Testing
- Proof Lab Test System
- Where
- 3 sites in United States
- Volunteers
- 276 people
- Sponsor
- Proof Diagnostics
SARS-CoV2 Infection, COVID-19
IMM-BCP-01 in Mild to Moderate COVID-19
The primary objective of this study is to evaluate the safety and tolerability of intravenous (IV) IMM-BCP-01 in subjects with mild to moderate COVID-19 through Day 28.
- Trial name
- NCT05429021
- Testing
- IMM-BCP-01
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Immunome, Inc.
COVID-19
Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine
Observer-blind, randomized, active-controlled prospective intervention study
- Trial name
- NCT05433285
- Testing
- COVID-19 Protein Subunit Recombinant Vaccine, Active Comparator
- Where
- 4 sites in Indonesia
- Volunteers
- 4,050 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
COVID-19, COVID-19 (SARS-CoV-2 Infection)
Evaluation of the Safety and Efficacy of Autologous COVID-19 Antigen Specific T Cell in Prolonged SARS-CoV-2 Patients
The goal of this clinical study is to evaluate the safety and efficacy of autologous COVID-19 antigen specific T cell (LB-DTK-COV19) treatment in prolonged SARS-CoV-2 infected patients.
- Trial name
- NCT07690943
- Testing
- LB-DTK-COV19
- Where
- South Korea
- Volunteers
- 13 people
- Sponsor
- LucasBio
COVID-19, SARS-CoV-2
Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults
The aim of the study is to assess the safety, and immunogenicity of AZD2816 for the prevention of coronavirus disease 2019 (COVID-19).
- Trial name
- AZD2816 (NCT04973449)
- Testing
- AZD1222, AZD2816
- Where
- 35 sites in Brazil, Poland and 2 more
- Volunteers
- 2,843 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Stroke, Acute, COVID-19
EPISODE-PS-COVID: hEad Pulse for Ischemic StrOke DEtection Prehospital Study During the COVID-19 Pandemic ( EPISODEPSCOVID )
Prehospital providers encounter patients with suspected stroke frequently. Stroke and COVID-19 are related potentially putting these healthcare workers at risk of COVID-19 infection.
- Trial name
- EPISODE-PH-COV (NCT04445493)
- Testing
- MindRhythm Harmony
- Where
- United States
- Volunteers
- 486 people
- Sponsor
- MindRhythm, Inc.
COVID-19
Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia
To explore the efficacy and confirm the safety of the concomitant administration of the standard of care and hzVSF-v13 in patients with COVID-19 infection
- Trial name
- NCT04679350
- Testing
- hzVSF-v13
- Where
- 3 sites in South Korea
- Volunteers
- 1 people
- Sponsor
- ImmuneMed, Inc.
COVID-19
Booster Study of COVID-19 Protein Subunit Recombinant Vaccine
Observer-blind, randomized, active-controlled prospective intervention study of Immunogenicity \& Safety of SARS-Cov-2 Protein Subunit Recombinant Vaccine (Bio Farma) as a Booster Dose Against COVID-19 in Adults 18 Years of Age…
- Trial name
- NCT05525208
- Testing
- SARS-CoV-2 subunit protein recombinant vaccine, Active Comparator
- Where
- 2 sites in Indonesia
- Volunteers
- 696 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Post-COVID-19 Syndrome
Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome
This study is a Phase 2, 24-week, randomized, prospective, double-blind, multicenter study in patients experiencing neuropsychiatric symptoms and functional impairment in the course of PASC.
- Trial name
- NCT05497089
- Testing
- Temelimab 54mg/kg
- Where
- 14 sites in Italy, Spain and 1 more
- Volunteers
- 203 people
- Sponsor
- GeNeuro SA
SARS-CoV-2, COVID-19
Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years
The purpose of this post-marketing study is to assess the safety of Comirnaty monovalent XBB.1.5. for booster vaccination children ages 6 months though 4 years under actual use medical practice.
- Trial name
- NCT06130410
- Testing
- COMIRNATY intramuscular injection
- Where
- Japan
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.